$NTRA

RABINOWITZ DANIEL sold $8.5M of NTRA

RABINOWITZ DANIEL (SEC. AND CHIEF LEGAL OFFICER) sold 33,600 shares of Natera, Inc. (NTRA) at an average of $251.65 ($250.25–$253.39, $8.46M total) across 4 trades on 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RABINOWITZ DANIEL
Published Jun 27, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 27, 2026, 1:34 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure updates the record of insider activity (legal officer selling shares) but does not introduce new operational, financial, or regulatory information about Natera.

02

Market read

Traders may treat this as a modest sentiment datapoint rather than a catalyst, given the pre-arranged 10b5-1 structure and lack of fundamental updates.

03

What to watch

The article provides sale size, price range, and post-trade holdings but no context on total compensation, prior sales cadence, or whether other insiders also sold around the same window.

Relevance 5/10Novelty 3/10Timing: Filed 2026-06-26 for sales executed 2026-06-24

Background

This is an SEC Form 4 insider transaction disclosure for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera Form 4 shows Daniel Rabinowitz (SEC and Chief Legal Officer) sold 33,600 shares in open-market trades under a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any effect would be sentiment/supply-related rather than fundamental.

Evidence & confidence

The filing is a primary-source insider transaction with defined dates/prices, but it does not disclose new company fundamentals or guidance changes.

Market effects

No direct sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, large insider sales can coincide with periods of valuation risk or personal liquidity needs, so traders may still watch for follow-on selling.

Key entities

  • Natera, Inc.

    Issuer of the Form 4 insider transaction; shares sold by its SEC and Chief Legal Officer.

  • Daniel Rabinowitz

    Natera officer (SEC and Chief Legal Officer) who executed open-market sales under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

$NTRAMedAI 8/10

Natera (NTRA) Q2 2026 Earnings Call Transcript

Natera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.